• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

New double C-loop haptics improve stability for novel trifocal IOL technology


A new trifocal IOL with double C-loop haptics (Micro F FineVision, PhysIOL) delivers excellent outcomes based on the benefits of its optic features and haptics.


Take Home

A new trifocal IOL with double C-loop haptics (Micro F FineVision, PhysIOL) delivers excellent outcomes based on the benefits of its optic features and haptics.



By Cheryl Guttman Krader; Reviewed by Camille Budo, MD

Maastricht, Netherlands-Previous experience with a trifocal IOL (MicroF FineVision, PhysIOL) show it provides excellent uncorrected visual acuity (BCVA) at all distances. Now, recent outcomes data indicate that a new version of the trifocal IOL featuring double C-loop haptics (POD F/FineVision, PhysIOL) can deliver the same spectacle independence and with better in-the-bag stability, reported Camille R. Budo, MD.

More in this issue: Fluid-based injectable IOL maintains stability in capsular bag

“Preliminary functional results achieved with the new POD F IOL combined with other data showing the positional stability provided by the double C-loop haptics design also provide clinical validation of this platform for the next FineVision trifocal toric IOL,” said Dr. Budo, associate professor of ophthalmology, University of Maastricht, Maastricht, The Netherlands.

Breaking it down

The double C-loop trifocal IOL is made of a hydrophilic acrylic material (26% water content) and can be implanted through a 2.2 mm incision. It has a 6 mm, aspheric diffractive trifocal optic with a 360° square edge. The trifocal design is achieved by the superimposition of 2 bifocal patterns:

·      For intermediate vision with a +1.75 D add.

·      For near vision with a +3.5 D add.

The lens has an overall diameter of 11.4 mm. The haptics have a 5° angulation, and the double C-loop design provides greater IOL stability in the capsular bag compared with closed loop haptics, Dr. Budo said.


“The double C-loop design improves both IOL rotational stability and axial stability for a more predictable effective lens position,” he explained.

Dr. Budo demonstrated the stability of the double-C loop platform by presenting data collected by Christophe Chassain, MD, Montpelier, France, who implanted a monofocal optic IOL with the double C-loop haptics in a series of more than 100 eyes followed through 15 months.

Analyses of rotation showed a mean change of 2.35° from the day of implantation to month 3, and of 2.5° from month 3 to month 12. The lens remained well-centered, and its anteroposterior stability was demonstrated by the stability of BCVA and SE outcomes comparing data collected at week 1, 3 months, and 15 months.

Further evidence

Regarding outcomes with the POD F double-C loop trifocal IOL, Dr. Budo presented preliminary visual acuity results from a series of 5 patients who underwent bilateral implantation, and he compared them with 6-month outcomes from 78 patients he implanted with the predecessor trifocal IOL (MicroF FineVision, PhysIOL) that features the same optic design, but uses a slightly different hydrophilic acrylic material (25% water content) and has a closed 4-loop haptic design.

At 10 days of follow-up, eyes implanted with the POD F had a mean distance UCVA of 0.77, mean CDVA of 0.8, mean intermediate UCVA of 0.9 and mean near UCVA of 0.69. Results for these endpoints in the Micro F IOL group were 0.85, 0.95, 0.79, and 0.83, respectively.

“The data from the POD F group are very early, but it seems some patients need more time to achieve better visual acuity, particularly for far,” Dr. Budo said.


Camille Budo, MD

E: camille.budo@gmail.com

Dr. Budo is medical advisor for PhysIOL.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.